Dyne Therapeutics, Inc.
DYN
$20.09
$0.100.50%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 16.67M | 16.56M | 15.93M | 15.30M | 12.86M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 113.89M | 115.79M | 122.37M | 97.11M | 105.66M |
| Operating Income | -113.89M | -115.79M | -122.37M | -97.11M | -105.66M |
| Income Before Tax | -108.04M | -110.86M | -115.36M | -89.54M | -97.13M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -108.04M | -110.86M | -115.36M | -89.54M | -97.13M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -108.04M | -110.86M | -115.36M | -89.54M | -97.13M |
| EBIT | -113.89M | -115.79M | -122.37M | -97.11M | -105.66M |
| EBITDA | -113.37M | -115.29M | -121.87M | -96.66M | -105.22M |
| EPS Basic | -0.76 | -0.97 | -1.05 | -0.88 | -0.96 |
| Normalized Basic EPS | -0.48 | -0.61 | -0.66 | -0.55 | -0.60 |
| EPS Diluted | -0.76 | -0.97 | -1.05 | -0.88 | -0.96 |
| Normalized Diluted EPS | -0.48 | -0.61 | -0.66 | -0.55 | -0.60 |
| Average Basic Shares Outstanding | 141.81M | 113.87M | 109.91M | 101.98M | 100.88M |
| Average Diluted Shares Outstanding | 141.81M | 113.87M | 109.91M | 101.98M | 100.88M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |